Investor Update May 4° 2017 ANGIOCRINE Bioscience EFTA00292520

--=PAGE_BREAK=--

Fact: Endothelial Cells Instruct Stem Cells Endothelial Cells —Y - Angiocrine Factors Signaling proteins Organ-Specific Stem Cells XO This is how vital organs in humans regenerate EFTA00292521

--=PAGE_BREAK=--

Uniquely Angiocrine Bioscience E-CEL™ Injectable engineered human endothelial cells that can orchestrate regeneration of vital organs W-CEL™ Create your own stem cells from your own endothelial cells obtained via skin or fat samples No other company has technologies like ours BIosCcIlaNncé EFTA00292522

--=PAGE_BREAK=--

Rapid Progress Over the Last Year 1) Awarded non-dilutive $3.8M grant for pre-clinical development 2) Created two clinical therapeutic candidates 3) Filed with FDA 1* Investigational New Drug (IND) application to enter clinic 4) New IP in cellular biopharmaceutical and stem cell gene therapy 5) Established full R&D capabilities in San Diego CALIFORNIA STEM CELL AGENCY ANGOCRING EFTA00292523

--=PAGE_BREAK=--

E-CEL™ Clinical Development Focus on Transforming Hematology & Oncology 1. E-CEL Stem-Cell Gene Therapy * Goal: Cure genetic blood diseases(e.g., Sickle Cell Anemia) * Clinical stage: H2 2017 (1* trial, Leukemia with high-risk genetic characteristics) 2. E-CEL Cellular Therapy * Goal: Accelerate recovery from radiation/chemotherapy © * Clinical stage: H1 2018 (1* trial, various cancers) —_— EFTA00292524

--=PAGE_BREAK=--

Substantial Global Markets Gene Therapy Market Cancer Care Market * Genetic diseases (e.g. Sickle Cell ¢ 40% of adults will be Anemia, Primary Immuno-Deficiency, diagnosed with cancer during etc.) are responsible for a heavy their lifetimes? loss of life.” ; * 1,685,210 new US cancer * > 6,000 known single-gene cases diagnosed in 20165 defect disorders age . * Significant number of patients Me e 4 . . . . worth USD 11 billion by will receive high-dose ” 2025 chemotherapy and/or * “an area of important future radiation treatment growth” (GlaxoSmithKline)* — www. who.int/genomics/public/geneticdiseases/en/index2.htm! * MIT Technology Review, May 16" 2016, Gene Therapy's First Out-and-Out Cure — 2www.medicinenet.com/genetic_disease/article.htm is Here. ANGI OCRIN E 3 www. pmewswire.com/news-releases/gene-therapy-market-2015- --2025-300082822.htm! is Here. 5Cancer Statistics - National Cancer Institute 2016 EFTA00292525

--=PAGE_BREAK=--

E-CEL Stem-Cell Gene Therapy Program CIRM Funded Phase 1b Trial Phase 2 Trial (Sickle Cell Anemia) Pre-Clinical & (Leukemia with high- IND risk genetic profile) Done H2-2017 H2-2019 BIOSCcIaNCcéE EFTA00292526

--=PAGE_BREAK=--

Clear US FDA Regulatory Path E-CEL Stem-Cell Gene Therapy First-In-Human Clinical Trial (Phase 1b) ¢ Safety of stem cells expanded in culture with E-CEL cells ¢ Stem cells are not gene corrected and obtained from donor umbilical cord blood (allogeneic) * Patients with blood/marrow cancer with high-risk genetic profile Second Clinical Trial (Phase 2) ¢ Safety and efficacy of stem cells expanded in culture with E-CEL cells ¢ Stem cells are gene corrected and obtained from patient’s bone marrow (autologous) * Patients with genetic blood disease (e.g., sickle cell anemia) ~~ — ANGIOCRINE EFTA00292527

--=PAGE_BREAK=--

First-in-Human Clinical Trial E-CEL Stem-Cell Gene Therapy Financial Support from: State of California Stem Cell Research and Cures Initiative publicly funded program to advance scientific discoveries in stem cell biology CALIFORNIA'S STEM CELL AGENCY * Pre-clinical grant award (April, 2016) - $3.8M Y Covered 80% of all pre-clinical development costs * Clinical grant application — (Q2, 2017) — up to $5M Y Covers 70% of Phase1b Clinical trial costs Therapeutic focus: ¢ Rebuild new blood and immune system by transplanting E-CEL cord blood stem cells (transplantation) in high-risk leukemia patients who cannot be cured by chemotherapy or other donors Key milestones: ¢ Submitted IND to enter first clinical trial in 2H17 * Clinical supply material manufactured in GMP facility for trial XO EFTA00292528

--=PAGE_BREAK=--

Phase 2 Clinical Trial E-CEL Stem-Cell Gene Therapy Ke NYSTEM New York’s publicly funded program to advance scientific discoveries in stem cell biology ¢ Award Amount - $15.7M ¢ Award Recipients: Consortium led by Angiocrine Scientific founder — Shahin X Raffi, MD (Weill Cornell Medical) and collaborator Michel Sadelain, MD (Memorial Sloan Kettering Cancer Center) Memorial Sloan Kettering Cancer Center... * Disease Focus: Sickle Cell Anemia * Purpose: * Combine Angiocrine’s E-CEL Technology with Sloan Kettering’s gene correction technology to develop a curative therapy for sickle cell disease * Funds research, pre-clinical development and IND XO Angiocrine retains commercial rights to E-CEL . BIOSCcrlaeNCcéE EFTA00292529

--=PAGE_BREAK=--

E-CEL Cellular Therapy Program Phase 1b Pre-Clinical & Clinical Trial IND (High-Dose Chemo/ Phase 2 Clinical Trial (High-Dose Chemo/ Radiation Recovery) On-going H1-2018 — — Radiation Recovery H1-2020 EFTA00292530

--=PAGE_BREAK=--

2.5 1.5 0.5 E-CEL Infusion Accelerates Blood & Immune System Recovery White Blood Cells Red Blood Cells RECOVER Platelets Day7 Day14 Day 21 Day 28 12 1200 10 1000 8 800 6 600 4 400 2 200 : 0 0 Day7 Day14 Day21 Day 28 Day7 Day14 Day 21 Day 28 === Control === Treated with E-CEL a NO Immunocompetent C57BL/6 mice — Treatment Day +1 post-LD50 irradiation EFTA00292531

--=PAGE_BREAK=--

AN Bios And Also... Systemic Recovery rene Normal No Treatment E-CEL Treated ae A tger - Spleen Bone Marrow Intestine No Radiation Day 28 Post-lrradiation EFTA00292532

--=PAGE_BREAK=--

Multiple Clinical Applications of E-CEL™ Applies to virtually all organ regeneration * Brain & Spine * Heart \ st ini . * Lungs 4 1* Clinical Focus: Bone Marrow * Liver (Blood & Immune System) * Kidneys * Muscles & =~, Tendons BIOoSCcrlaNncéE EFTA00292533

--=PAGE_BREAK=--

Angiocrine’s Active Research Pipeline Partnering with Experts — Resource Efficient W-CEL™ Stem Cells Neural E-CEL Lung E-CEL Liver E-CEL Tendon/Muscle E-CEL E-CEL Gene Therapy ANGOCRING Produce one’s own blood stem cells from own fat Restore function in spinal cord me SPINAL CORD J) weit Comell Medical College _ RESEARCH CENTER injury Restore function in chronic lung (=) Weill Comell Medical College disease SZ Repair without fibrosis in chronic . . | Weill Cornell Medical College liver disease Accelerate healing, strengthen o7) HOSPITAL FOR tendon repair s) SPECIAL SURGERY Treat and cure HIV patients with Cityof Hope Lymphoma RESEARCH - TREATMENT ~ CURES EFTA00292534

--=PAGE_BREAK=--

Angiocrine Research: W-CEL Technology Create your own stem cells from your skin or fat sample Transformative potential for longevity and rejuvenation science Direct Conversion of Adult Endothelial Cells into Immune- Competent Long-Term Engraftable Clinically Scalable Hematopoietic Stem Cells: Pathway to Therapeutic Translation Lis R et. al., Blood 2016 128:372; | {S|} Weill Cornell Medical College NATURE | VOL 511/17 JULY 2014 Reprogramming human endothelial cells to haematopoietic cells requires vascular induction Viadistay M. Sandier', Raphael Lis', Ying Liu', Alon Kedem!’, Daylon James™, Olivier Elemento", Jason M, Butler’ hahin Rafi" ANGIOCRINE Joseph M. Scandura* & Si EFTA00292535

--=PAGE_BREAK=--

ANGOCRIN Series A-1 Equity Financing Pre-Money Valuation: $27M Minimum raise: $4M Maximum: $8M | Series A-1 | Proceeds towards objectives: S4M ‘matching’ funds to obtain additional $SM CIRM clinical grant for 1%t E-CEL study & complete trial > S6M + advance E-CEL chemo/rad recovery to 24 IND + in-license gene therapy vector (e.g., sickle cell) > $8M + complete 24 IND (cancer chemo/rad treatment recovery program) & apply for 2"? SSM CIRM grant + initiate pre-clinical gene therapy studies Broscrance EFTA00292536

--=PAGE_BREAK=--

Anticipated Inflection Points aera ‘safety 1° Data nate pail ria afe . Tria Safety H2-2017 H1-2018 H1-2015 H2-2019 H2-2020 E-CEL Stem-Cell Phase 1b Trial Phase 2b Trial Gene Therapy (High-Risk Leukemia) (Sickle Cell Anemia) Initiate Interim ° Initiate Trial Safety 1° Data Trial H1-2018 H2-2018 H2-2019 H2-2020 ¥y Ff fF E-CEL Cellular Therapy pheceabaral Phase 2/3 (Cancer Care Recovery) Trial April2017 EFTA00292537

--=PAGE_BREAK=--

Angiocrine Bioscience Investment Thesis 1. Prior to value inflection points ¢ Transition to clinical stage * Two clinical assets * Expanding pipeline & partnerships 2. Risk-mitigated: ¢ Multiple shots to succeed ¢ Pre-clinical toxicology done on E-CEL * Thoroughly vetted by experts (grants, publications) ¢ Value in robust IP 3. Leveraged: opportunity for more non-dilutive grants 4. Experienced Leadership: solid records, prior exits BIOSCIaNCES EFTA00292538

--=PAGE_BREAK=--

THANK YOU! Contacts: Paul _— = MBA - CEO John Jaskowiak - _ ——— Development E-CEL™ Therapies W-CEL™ Technology Transforming Hematology and Cancer Care Apel 2087 via the powers of CXO Engineered Endothelial Cells ANGOCRING EFTA00292539